News

Cancer Genetics, Inc. Announces Acquisition of Premier Genomics and Next Generation Sequencing Company, BioServe India

By Jamie on May 15 2014

The Acquisition Positions CGI to Immediately Participate in The High Growth Indian Molecular Diagnostics and Oncology Services Market Further Extends Next-Generation Sequencing Capabilities By Leveraging BioServe India’s Capabilities & Development Roadmap Acquisition Adds Immediate Revenue, Valuable Client Base and is Expected To Be Cash Neutral in 2014 and Accretive in Fiscal 2015 Immediately Provides CGI […]

Continue Reading

Cancer Genetics CEO Moderates Panel Discussion With Thought Leaders in Biopharma at the BioNJ 2014 International BioPartnering Conference

By Jamie on April 10 2014

Panna Sharma, CEO of Cancer Genetics, Is Moderating a Panel Entitled “Partnering for a Balanced Portfolio:  Perspectives from Innovators, Partners, & Payers” RUTHERFORD, N.J., April 10, 2014 – Cancer Genetics, Inc. (Nasdaq: CGIX) (“CGI” or the “Company”), an emerging leader in DNA-based cancer diagnostics, announced that the Company is a sponsor of the BioNJ International […]

Continue Reading

Cancer Genetics Announces Launch of CALR Mutation Analysis Test to Assist in Diagnosis of Acute Leukemias & Myeloproliferative Neoplasms

By Jamie on April 4 2014

New Test Launch Extends CGI’s Leadership in Genomic Testing for Blood Cancers CALR Genetic Mutation Test Will Be A Part of CGI’s Comprehensive Focus on Leukemia RUTHERFORD, N.J., April 4, 2014 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or the “Company”), an emerging leader in DNA-based cancer diagnostics, has launched a genetic diagnostic test for […]

Continue Reading

Cancer Genetics to Present New Data from Renal Cell Carcinoma Study at AACR

By Jamie on April 3 2014

Genomic Alterations Identified in Study Could Potentially Serve as Biomarkers for Metastasis in RCC RUTHERFORD, NJ – April 3, 2014 – Cancer Genetics, Inc. (NASDAQ: CGIX), an emerging leader in DNA-based diagnostics, announced today that a poster highlighting preliminary results of a study in clear cell Renal Cell Carcinoma (ccRCC) will be presented at the 105th Annual […]

Continue Reading

CGI’s Proprietary DNA-based Test For Cervical Cancer, FHACT™, Adopted By Leading Kamineni Hospital Group in India For The Diagnosis and Triaging of Cervical Cancer

By Italia on March 20 2014

There are over 123,000 new cervical cancer cases in India each year where it is a leading cause of cancer mortality, causing 17% of deaths in women 30-69 years of age. Adoption of  FHACT™ cervical cancer test by Kamineni Hospitals positions CGI to significantly improve women’s health in India. RUTHERFORD, N.J., Mar. 20, 2014 — Cancer […]

Continue Reading

Cancer Genetics Appoints Edward J. Sitar as Chief Financial Officer

By Italia on March 17 2014

Seasoned Financial Executive Will Support Company’s Continued Growth and Focus on Reimbursement and Payers RUTHERFORD, NJ – March 17, 2014 – Cancer Genetics (NasdaqCM: CGIX), an emerging leader in DNA-based diagnostics, announced today that effective April 1, 2014, it has appointed Edward J. Sitar, CPA as Chief Financial Officer.  Mr. Sitar will be responsible for […]

Continue Reading

Cancer Genetics, Inc. Adds Additional Kidney Cancer Patent to its Portfolio

By Italia on February 26 2014

CGI Receives Notice of Allowance for Its Proprietary Kidney Cancer Test, Further Strengthening the Company’s IP Portfolio RUTHERFORD, N.J., Feb. 26, 2014 — Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or the “Company”), an emerging leader in DNA-based diagnostics, today announced that the United States Patent and Trademark Office (USPTO) has allowed its patent claims related to […]

Continue Reading

Cancer Genetics, Inc. Announces a New Breakthrough for Diagnosis and Prediction of Kidney Cancer Outcomes Using Its Proprietary Genomic Test

By Italia on February 24 2014

Significant Advancement in the Classification and Prediction of Kidney Cancer Outcomes Validated in Collaborative 191 Patient Clinical Study with Cleveland Clinic Using CGI’s Genomic Microarray Test New Data to Be Presented at USCAP Annual Meeting by Cleveland Clinic’s Dr. Magi-Galuzzi on Monday, March 3 RUTHERFORD, N.J., Feb. 24, 2014 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. […]

Continue Reading

Cancer Genetics, Inc. New Clinical Trial Backlog Exceeds $13 Million

By Italia on February 20 2014

Rutherford, NJ – February 20, 2014 – Cancer Genetics, Inc. (NasdaqCM: CGIX) (“CGI” or the “Company”), an emerging leader in DNA-based diagnostics, initiated two additional multi-year clinical trial contracts with biopharmaceutical customers. The Company estimates that the new contracts increase its total SelectOneTM pipeline to over $13 million in revenue over the next two years. CGI’s SelectOne program […]

Continue Reading

Cancer Genetics is Pleased to Announce The Appointment of Dr. Paul Rothman, Dean of the Medical Faculty and CEO of Johns Hopkins Medicine, to its Board of Directors

By Jamie on February 18 2014

RUTHERFORD, NJ – February 18, 2014 – Cancer Genetics (NasdaqCM: CGIX), an emerging leader in DNA-based diagnostics, announced today the addition of Paul Rothman, MD, Dean of the Medical Faculty and CEO of Johns Hopkins Medicine, to the Company’s Board of Directors. As Dean and CEO, Dr. Rothman oversees both the Johns Hopkins Health System and the School of Medicine.  He […]

Continue Reading